Preparation method of cationic liposome SM-102 and Lipid5

Through the transesterification method, solvent-free decompression dehydration method and direct extraction method combined with the recrystallization method of specific organic acid salts, SM-102 and Lipid5 are efficiently synthesized, solving the problems of cumbersome operation and low yield in the prior art, and realizing the problem of "complexity in operation" and "low yield" Massive production with high efficiency and high purity.

CN114874104BActive Publication Date: 2024-11-29HUBEI YINGNASHI BIOTECHNOLOGY CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202210465604.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-29
Publication Date
2024-11-29
Estimated Expiration
2042-04-29

AI Technical Summary

Technical Problem

In the prior art, the synthesis method of SM-102 and Lipid5 is complicated to operate, has low yield, and is difficult to achieve preparation of above 100 grams, and has poor selectivity and pollution problems.

Method used

The key intermediate secondary alcohol esters 8-bromooctanoate-9-heptyl alcohol esters were synthesized by transesterification method, and 6-bromoenoate-undecolate and 8-bromooctanoate-nonanol esters were synthesized by solvent-free dehydration method. , 6-ethanolamine-hexanoate-undecolate and 8-ethanolamine-octanoate-nonanol ester were synthesized by direct extraction of alkanes or aromatic solvents, and the recrystallization method combined with specific organic acid salts was achieved to achieve SM-102 and High-efficiency purification and separation of Lipid5.

Benefits of technology

It solves the problems of difficulty in control, long time, poor selectivity, cumbersome operation and great pollution in traditional synthesis reactions, improves the preparation efficiency and purity of SM-102 and Lipid5, and achieves large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure QLYQS_1
    Figure QLYQS_1
Patent Text Reader

Abstract

The invention discloses a preparation method of a cationic liposome SM-102 and its analogs, and belongs to the technical field of organic synthesis. The invention creatively adopts an ester exchange method to synthesize a key intermediate secondary alcohol ester 8-bromooctanoic acid-9-heptadecanol ester, a solvent-free vacuum dehydration method to synthesize 6-bromohexanoic acid-undecyl ester and 8-bromooctanoic acid-nonanol ester, an alkane solvent or an aromatic solvent direct extraction method to synthesize 6-ethanolamine-hexanoic acid-undecyl ester and 8-ethanolamine-octanoic acid-nonanol ester, and a specific organic acid salt crystallization method to synthesize, purify and separate SM-102 and Lipid 5. The invention solves the problems of being difficult to control, taking a long time, having poor selectivity, being complicated and difficult to operate, having a low yield and being highly polluted in traditional synthetic reactions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of organic synthesis, and in particular to a method for preparing cationic liposome SM-102 and Lipid5. Background Art

[0002] Liposomes were first discovered under a microscope by scientists Alec Douglas Bangham and RW Horne in 1961. Liposomes are vesicle structures composed of lipid molecules, with a lipid bilayer forming a hydrophobic shell and an internal aqueous cavity, and have both hydrophilic and hydrophobic properties.

[0003] This property makes liposomes an ideal carrier for drug delivery. In 1995, the US FDA approved the first liposome drug Doxil. Doxil uses HSPC / DMG-PEG two-component liposomes to encapsulate the drug doxorubicin for ovarian cancer and breast cancer chemotherapy to reduce the toxicity of free drugs to other organs.

[0004] In the formulation of lipid nanoparticles encapsulating nucleic acids, the key role is played by ionizable lipids or cationic liposomes, whose pKa values ​​are generally between 6.3-6.5. This feature makes its surface charge basically neutral in the serum environment, which is conducive to the cells to swallow the lipid nanoparticles carrying nucleic acid fragments into the cells as a whole to form endosomes. Once entering the cell, the acidic environment of the endosome causes the head of the ionized lipid to be protonated and positively charged, thereby fusing with the inner membrane of the endosome and releasing the target nucleic acid into the cell to play a role. Thanks to the early optimization of mRNA and a large amount of basic research and testing on lipid nanoparticles, the development of the mRNA vaccine for the new coronavirus Covid-19 took less than a year from the virus sequence to the successful launch. This was unimaginable and unachievable in the past. In the mRNA vaccine for the new coronavirus Covid-19, Moderna used the self-developed ionizable lipid SM-102.

[0005] The chemical cas number of SM-102 is 2089251-47-6, and its structure is shown below

[0006]

[0007] Other analogs also show good structures, such as Lipid 5, with cas number 2089251-33-0, and its structure is shown below:

[0008]

[0009] European patents WO2017049245A2 and WO2018081480A disclose methods for synthesizing SM-102. Each step requires column chromatography separation and purification. The operation is cumbersome and the yield is low, and it is basically impossible to achieve synthesis above 100 grams. Summary of the invention

[0010] In order to solve the above problems, the present invention provides a method for preparing cationic liposome SM-102 and Lipid5. The present invention creatively adopts the ester exchange method to synthesize the key intermediate secondary alcohol ester 8-bromooctanoic acid-9-heptadecanol ester, the solvent-free vacuum dehydration method to synthesize 6-bromohexanoic acid-undecyl ester and 8-bromooctanoic acid-nonanol ester, the alkane solvent or aromatic solvent direct extraction method to synthesize 6-ethanolamine-hexanoic acid-undecyl ester and 8-ethanolamine-octanoic acid-nonanol ester, and the specific organic acid salt (the specific salt has low solubility in the recrystallization solvent, the product of this embodiment is liquid, and the generated salt is equivalent to a surfactant, which has high solubility in most solvents and is difficult to separate) crystallization method to synthesize, purify and separate SM-102 and Lipid 5. The problems of difficult control, long time, poor selectivity, complicated and difficult operation, low yield and high pollution in traditional synthesis reactions are solved.

[0011] The embodiment of the present invention provides a method for preparing cationic liposome SM-102 and Lipid5, comprising:

[0012] (1) 8-bromooctanoic acid ester is esterified to obtain 8-bromooctanoic acid methyl ester.

[0013] (2) In an organic solvent A, 8-bromooctanoic acid methyl ester and 9-heptadecanol are subjected to an ester exchange reaction under the action of a catalyst B to obtain 8-bromooctanoic acid-9-heptadecanol ester. The reaction temperature is 70-100° C. (preferably 80-90° C.), and the molar ratio of 8-bromooctanoic acid methyl ester to 9-heptadecanol is 1:1-3 (preferably 1:1.05-2).

[0014] In the prior art, organic acids and alcohols can react directly, but in this patent, 9-heptadecanol is a secondary alcohol with a large steric hindrance. If the esterification reaction is directly carried out, the yield is less than 10%. In addition, in step (2), a special catalyst is used to improve the reaction yield according to the special structure of the reactants (the yield of the conventional ester exchange catalyst used in this patent is less than 20%, and the yield of the conventional condensation agent condensation method is about 40-50%); in addition, step (2) uses 80-90°C for the reaction in order to allow the by-products to just separate from the reactants and promote equilibrium shift.

[0015] (3) Compound A and compound B react under the action of catalyst C to obtain compound C. Compound A is selected from alcohols with a relatively high molecular weight of undecanol or nonanol, compound B is selected from omega-bromo fatty acids such as 6-bromohexanoic acid or 8-bromooctanoic acid, and compound C is selected from esters corresponding to 6-bromohexanoic acid-undecanol ester or 8-bromooctanoic acid nonanol ester. The reaction temperature is 60-100° C., the reaction pressure is 10-20 mmHg, and the molar ratio of compound A to compound B is 1:1-3 (preferably 1:1.05-2). Specifically, 6-bromohexanoic acid-undecanol ester is obtained by reacting 6-bromohexanoic acid with undecanol, and 8-bromooctanoic acid nonanol ester is obtained by reacting 8-bromooctanoic acid with nonanol. Compound A serves as both a reactant and a reaction solvent.

[0016] The organic acid and alcohol in this step can be directly subjected to conventional esterification reaction, and the reaction is simple.

[0017] (4) In an organic solvent B, compound C reacts with ethanolamine to obtain compound D. Compound D is selected from 6-ethanolamine-hexanoic acid-undecanol ester or 8-ethanolamine-octanoic acid-nonanol ester, the reaction temperature is 20-70°C (preferably 20-50°C), and the molar ratio of compound C to ethanolamine is 1:3-15 (preferably 1:5-15). Specifically, 6-bromohexanoic acid-undecanol ester reacts with ethanolamine to obtain 6-ethanolamine-hexanoic acid-undecanol ester, and 8-bromooctanoic acid-nonanol ester reacts with ethanolamine to obtain 8-ethanolamine-octanoic acid-nonanol ester.

[0018] In this process, ethanolamine must be in very large excess, and it has at least three functions: first, to ensure that only one hydrogen atom on the ethanolamine is replaced; second, to react with the reaction by-product hydrobromic acid; and third, to act as a catalyst to promote the reaction.

[0019] (5) In an organic solvent C, compound D and 8-bromooctanoic acid-9-heptadecanol ester are aminated under the action of catalyst D to obtain a crude compound E. Compound E is selected from SM-102, Lipid 5 or its analogs, the reaction temperature is 50-100° C. (preferably 60-85° C.), and the molar ratio of compound D to 8-bromooctanoic acid-9-heptadecanol ester is 1:1-3 (preferably 1:1.05-2.5); specifically, 6-ethanolamine-hexanoic acid-undecyl ester is reacted with 8-bromooctanoic acid-9-heptadecanol ester to obtain SM-102, and 8-ethanolamine-octanoic acid-nonanol ester is reacted with 8-bromooctanoic acid-9-heptadecanol ester to obtain Lipid 5.

[0020] In steps (4) and (5), ethanolamine must first react with compound C, and the resulting product is then reacted with 8-bromooctanoic acid-9-heptadecanol ester. The reason is that compound D can be crystallized as a solid in the extractant, which is easy to separate; while the product obtained by the reaction of 8-bromooctanoic acid-9-heptadecanol ester with ethanolamine is a liquid, which is difficult to separate and purify. In step (5), ethanolamine must be removed to avoid side reactions. In addition, since the amount of ethanolamine used is very large, the method of this patent can also facilitate the recovery and reuse of ethanolamine.

[0021] (6) The crude compound E reacts with an organic acid to obtain a salt, which is recrystallized and then reacted with a base B to obtain a refined compound E.

[0022] Wherein, step (1) specifically comprises: 8-bromooctanoic acid and methanol are subjected to esterification reaction under the action of catalyst A, the reaction temperature is 20-70°C, after the reaction is completed, base A is added to adjust to alkalinity, filtration and concentration are performed to obtain 8-bromooctanoic acid methyl ester. Wherein, catalyst A is selected from potassium hydrogen sulfate, sodium hydrogen sulfate, concentrated sulfuric acid or thionyl chloride, etc., preferably concentrated sulfuric acid; base A is selected from potassium carbonate or sodium carbonate, preferably sodium carbonate; the amount of methanol is 1-10:1 to the mass ratio of 8-bromooctanoic acid, and the amount of catalyst A is 0.1-5% of the mass of 8-bromooctanoic acid. In this step, methanol is used as both a reactant and a reaction solvent.

[0023] Wherein, in step (2), the organic solvent A is selected from petroleum ether, hexane, heptane, octane, benzene or toluene, and is preferably n-heptane or n-hexane. The catalyst B is selected from glycidol, glycidol methyl ether, glycidol phenyl ether or 2-ethylene-propionic acid-glycidol ester, and is preferably glycidol; the amount of catalyst B is 0.1-3% of the mass of 8-bromooctanoic acid methyl ester.

[0024] Wherein, in step (3), the catalyst C is selected from potassium hydrogen sulfate or sodium hydrogen sulfate, and is preferably potassium hydrogen sulfate. The amount of catalyst C used is 0.1-10% of the mass of compound A.

[0025] Wherein, in step (4), the organic solvent B is selected from methanol, ethanol, propanol, isopropanol or acetonitrile, and is preferably ethanol.

[0026] Wherein, in step (4), after the reaction is completed, the temperature is lowered, an extractant is added for extraction, the extract is cooled and crystallized, and the compound D is obtained by filtration. The extractant is selected from petroleum ether, hexane, heptane, octane, benzene or toluene, and is preferably n-heptane.

[0027] Wherein, in step (5), the organic solvent C is selected from acetonitrile, methanol, ethanol, propanol or isopropanol, etc., preferably acetonitrile; the catalyst D is selected from anhydrous potassium carbonate, anhydrous sodium carbonate, anhydrous potassium bicarbonate or anhydrous sodium bicarbonate, etc., preferably anhydrous potassium carbonate; the mass ratio of catalyst D to compound D is 10-60:100.

[0028] Wherein, in step (6), the organic acid is selected from tartaric acid, fumaric acid, maleic acid, citric acid, oxalic acid, succinic acid or benzoic acid, preferably fumaric acid; the molar ratio of the crude compound E to the organic acid is 1:1-2 (preferably 1:1.05-2); the recrystallization solvent is selected from petroleum ether, hexane, heptane, octane, benzene or toluene, preferably n-hexane or n-heptane. The base B is preferably aqueous ammonia, especially preferably aqueous ammonia with a high concentration.

[0029] Specifically, the preparation method of cationic liposome SM-102 and Lipid5 provided in the embodiment of the present invention includes:

[0030] (1) 8-bromooctanoic acid and methanol are subjected to esterification reaction under the action of concentrated sulfuric acid at a reaction temperature of 20-70° C. After the reaction is completed, sodium carbonate is added to adjust the reaction to alkalinity, and the reaction is filtered and methanol is recovered to obtain 8-bromooctanoic acid methyl ester. The mass ratio of methanol to 8-bromooctanoic acid is 1-10:1, and the amount of concentrated sulfuric acid used is 0.1-5% of the mass of 8-bromooctanoic acid.

[0031] (2) In n-heptane, 8-bromooctanoic acid methyl ester and 9-heptadecanol are subjected to ester exchange reaction under the action of propylene oxide, and the reaction temperature is 80-90° C. After the reaction is completed, the n-heptane is recovered to obtain 8-bromooctanoic acid-9-heptadecanol ester, the molar ratio of 8-bromooctanoic acid methyl ester to 9-heptadecanol is 1:1.05-2, and the amount of propylene oxide used is 0.1-3% of the mass of 8-bromooctanoic acid methyl ester.

[0032] (3) Compound A and Compound B react under the action of potassium hydrogen sulfate at a reaction temperature of 60-100° C. and a reaction pressure of 10-20 mmHg. After the reaction is completed, the compound C is obtained by filtration. The molar ratio of compound A to compound B is 1:1.05-2, and the amount of potassium hydrogen sulfate used is 0.1-10% of the mass of compound A.

[0033] (4) Compound C reacts with ethanolamine in ethanol at a reaction temperature of 20-50° C. After the reaction is completed, the temperature is lowered, and the extract is extracted with n-heptane. The extract is crystallized at -10-5° C., and the extract is filtered to obtain compound D. The molar ratio of compound C to ethanolamine is 1:5-15.

[0034] (5) In acetonitrile, compound D and 8-bromooctanoic acid-9-heptadecanol ester are subjected to an amination reaction under the action of anhydrous potassium carbonate and nitrogen protection, the reaction temperature is 60-85°C, after the reaction is completed, the mixture is filtered, rinsed with n-hexane or n-heptane, fumaric acid is added to the filtrate (containing the crude compound E), the temperature is lowered for crystallization, filtered, the solid is recrystallized in n-hexane or n-heptane, ammonia water is added to adjust the pH value to alkaline, anhydrous sodium sulfate is added to dry until the solution is clear, filtered, and n-hexane or n-heptane is recovered to obtain compound E, the molar ratio of compound D and 8-bromooctanoic acid-9-heptadecanol ester is 1:1.05-2.5, the mass ratio of anhydrous potassium carbonate to compound D is 10-60:100, and the molar ratio of crude compound E to fumaric acid is 1:1.05-2. In this process, the product of fumaric acid and compound D has a low solubility in n-heptane and can be recrystallized. In addition, in this patent, it is best to add ammonia water to adjust the pH, and dry with anhydrous sodium sulfate to absorb excess water to avoid problems such as foaming of the reaction solution (the intermediate product is equivalent to a surfactant, which is prone to foaming in large quantities in the presence of water and strong alkali). BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 is the NMR spectrum of intermediate 2;

[0036] Figure 2 is the NMR spectrum of intermediate 3;

[0037] Figure 3 is the NMR spectrum of intermediate 4;

[0038] Figure 4 This is the NMR spectrum of SM-102;

[0039] Figure 5 The present invention discloses a nuclear magnetic spectrum of 8-bromooctanoic acid nonyl ester synthesized by the method of the present invention;

[0040] Figure 6 The present invention discloses a nuclear magnetic spectrum of 8-ethanolamine-octanoic acid-nonanol ester synthesized by the method of the present invention;

[0041] Figure 7 This is the NMR spectrum of Lipid-5. DETAILED DESCRIPTION

[0042] In order to make the objectives, technical solutions and advantages of the present invention more clear, the embodiments of the present invention are described in further detail below.

[0043] Examples 1 to 5 are the synthesis process of SM-102, and the reaction scheme is as follows:

[0044] .

[0045] Example 1 Preparation of 8-bromooctanoic acid methyl ester (intermediate 1)

[0046] In a 3000mL reaction bottle, 600g of 8-bromooctanoic acid, 2000ml of methanol and 10g of concentrated sulfuric acid were added, and the mixture was heated at 50-65°C until the reaction was completed. The mixture was cooled to room temperature, and sodium carbonate was added to make the mixture alkaline. The insoluble solid was removed by filtration, and methanol was recovered to obtain 605g of methyl 8-bromooctanoate with a yield of 95%.

[0047] Example 2 Preparation of 8-bromooctanoic acid-9-heptadecanol ester (Intermediate 2)

[0048] In a 5000mL reaction bottle, 600g of methyl 8-bromooctanoate, 650g of 9-heptadecanol, 2000ml of solvent n-heptane, and 10g of catalyst propylene oxide were added. The mixture was heated to 80-90°C and stirred for reaction for 8h. After the reaction was completed, n-heptane was recovered to obtain 1165g of colorless transparent liquid with a yield of 96%.

[0049] HNMR (300MHz, CDC1) δ: ppm4.89(m,1H);3.42(m,2H);2.31(m,2H);1.89(m,2H);1.73-1.18(m,36H);0.88(m,6H).

[0050] Example 3 Preparation of 6-bromohexanoic acid-undecanol ester (Intermediate 3)

[0051] Into a 3000L reaction bottle, 1000g of 6-bromohexanoic acid, 885g of undecanol, and 30g of potassium hydrogen sulfate catalyst were added. The water pump was used to reduce the pressure to 10-20mmHg. At the same time, the internal temperature was heated to 80-85°C. Water was evaporated. After about 5-6 hours of reaction, almost no water was evaporated. The reaction bottle had a constant weight and was cooled to room temperature. About 100g of silica gel was spread in a Buchner funnel. The reaction liquid was filtered to obtain 1718g of a light yellow transparent liquid with a yield of 96%.

[0052] HNMR (300 MHz, CDC1 ) δ: ppm 4.06 (t, 2H); 3.40 (t, 2H); 2.29 (t,2H); 1.85 (m,

[0053] 2H); 1.72-0.97 (m, 22H); 0.88 (m, 3H).

[0054] Example 4 Preparation of 6-ethanolamine-hexanoic acid-undecyl ester (Intermediate 4)

[0055] Add 1700g of 6-bromohexanoic acid undecyl ester, 3000g of ethanolamine and 170g of ethanol into a 5000L reaction bottle, heat to 45-50°C, stir and react for 12-16 hours, cool to room temperature after the reaction is completed, extract twice with 1000ml*2 n-heptane, crystallize the extract solution at -10-0°C, filter to obtain 1390g of white solid, with a yield of 87%.

[0056] HNMR (300 MHz, CDC1 ) δ: ppm 4.07 (t, 2H); 3.65 (t, 2H); 2.78 (t,2H); 2.63 (t,

[0057] 2H); 2.32-2.19 (m, 4H); 1.73-1.20 (m, 24H); 0.89 (m, 3H).

[0058] Example 5 Preparation of SM-102

[0059] 1160g of 8-bromooctanoic acid-9-heptadecanol ester, 80ml of acetonitrile, 1000g of 6-ethanolamine-hexanoic acid-undecanol ester, and 400g of anhydrous potassium carbonate were added to a 5000L reactor. The mixture was protected by nitrogen and heated to 75-80°C. The mixture was stirred for 10-16 hours until the reaction was complete. The inorganic salts were filtered out and rinsed twice with 1000ml*2 of n-heptane until there was no product in the solution. Fumaric acid was added to the filtrate and crystallized overnight at -10°C. The obtained solid was filtered out. 3000ml of n-heptane was added to the solid, and ammonia water was added to adjust the solution to alkalinity. Anhydrous sodium sulfate was added to dry the solution until it was clear. After filtering, n-heptane was recovered to obtain a light yellow transparent liquid SM-102 with a product mass of 1508g and a yield of 84%.

[0060] HNMR (300 MHz, CDC1 ) δ: ppm 4.86 (m, 1H); 4.05 (t, 2H); 3.68-3.46(m,2H); 2.77-2.37 (m, 5H); 2.29 (m, 4H); 1.74-1.41 (m, 14H); 1.39-1.18 (m,50H); 0.88 (m, 9H).

[0061] Example 6 Preparation of Lipid 5

[0062] 1160 g of 8-bromooctanoic acid-9-heptadecanol ester, 80 ml of acetonitrile, and 8-ethanolamine-octanoic acid-nonanol ester (the synthesis process can be referred to in Examples 3 and 4, the amount of 8-ethanolamine-octanoic acid-nonanol ester is the same as that of 6-ethanolamine-hexanoic acid-undecyl ester, and other conditions are the same. The NMR spectrum of 8-ethanolamine-octanoic acid-nonanol ester is as follows: Figure 6The mixture was stirred for 10-16 hours under nitrogen protection, and the inorganic salt was removed by filtration. The product was rinsed twice with 1000 ml of n-heptane until no product was left in the solution. Fumaric acid was added to the filtrate, and the mixture was crystallized overnight at -10 °C. The solid was filtered, and 3000 ml of n-heptane was added to the solid. Ammonia water was added to adjust the solution to alkalinity. Anhydrous sodium sulfate was added to dry the solution until it was clear. The n-heptane was recovered after filtration to obtain a light yellow transparent liquid Lipid 5. The product mass was 1448 g, and the yield was 81%.

[0063] H NMR (300 MHz, CDCI 3) δ: ppm 4.86 (m, 1H); 4.05 (t, 2H); 3.53 (m,2H); 2.83-2.36 (m, 5H); 2.29 (m, 4H); 0.96-1.71 (m, 64H); 0.88 (m, 9H).

[0064] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. Preparation method of cationic liposome SM-102 and Lipid5, It is characterized in that The method comprises: (1) 8-bromooctanoic acid esterification to obtain 8-bromooctanoic acid methyl ester; (2) in an organic solvent A, 8-bromooctanoic acid methyl ester and 9-heptadecanol are subjected to an ester exchange reaction under the action of a catalyst B to obtain 8-bromooctanoic acid-9-heptadecanol ester, the reaction temperature is 70-100° C., the molar ratio of 8-bromooctanoic acid methyl ester to 9-heptadecanol is 1:1-3, and the catalyst B is selected from glycidol; (3) Compound A and Compound B react under the action of catalyst C to obtain Compound C, wherein Compound A is selected from undecanol or nonanol, Compound B is selected from 6-bromohexanoic acid or 8-bromooctanoic acid, and Compound C is selected from 6-bromohexanoic acid-undecanol ester or 8-bromooctanoic acid nonanol ester, the reaction temperature is 60-100° C., and the molar ratio of Compound A to Compound B is 1:1-3; (4) in an organic solvent B, compound C reacts with ethanolamine to obtain compound D, wherein compound D is selected from 6-ethanolamine-hexanoic acid-undecanol ester or 8-ethanolamine-octanoic acid-nonanol ester, the reaction temperature is 20-70° C., and the molar ratio of compound C to ethanolamine is 1:3-15; (5) In an organic solvent C, compound D and 8-bromooctanoic acid-9-heptadecanol ester are subjected to amination under the action of catalyst D to obtain a crude compound E, wherein compound E is selected from SM-102 or Lipid 5, the reaction temperature is 50-100° C., and the molar ratio of compound D to 8-bromooctanoic acid-9-heptadecanol ester is 1:1-3; (6) The crude compound E reacts with an organic acid to obtain a salt, which is recrystallized and then reacted with a base B to obtain a refined compound E; The structural formula of SM-102 is as follows: ; The structural formula of Lipid5 is as follows: 。 2. The method for preparing the cationic liposome SM-102 and Lipid5 according to claim 1, It is characterized in that The step (1) specifically comprises: 8-bromooctanoic acid and methanol are subjected to an esterification reaction under the action of a catalyst A, the reaction temperature is 20-70°C, after the reaction is completed, a base A is added to adjust the alkalinity, filtering and concentrating to obtain 8-bromooctanoic acid methyl ester, the catalyst A is selected from potassium hydrogen sulfate, sodium hydrogen sulfate, concentrated sulfuric acid or thionyl chloride, the base A is selected from potassium carbonate or sodium carbonate, the mass ratio of methanol to 8-bromooctanoic acid is 1-10:1, and the amount of catalyst A used is 0.1-5% of the mass of 8-bromooctanoic acid.

3. The method for preparing the cationic liposome SM-102 and Lipid5 according to claim 1, It is characterized in that In step (2), the organic solvent A is selected from petroleum ether, hexane, heptane, octane, benzene or toluene, and the amount of catalyst B used is 0.1-3% of the mass of 8-bromooctanoic acid methyl ester.

4. The method for preparing the cationic liposome SM-102 and Lipid5 according to claim 1, It is characterized in that In step (3), the catalyst C is selected from potassium bisulfate or sodium bisulfate, and the amount of catalyst C used is 0.1-10% of the mass of compound A.

5. The method for preparing the cationic liposome SM-102 and Lipid5 according to claim 1, It is characterized in that In step (4), the organic solvent B is selected from methanol, ethanol, propanol, isopropanol or acetonitrile.

6. The method for preparing the cationic liposome SM-102 and Lipid5 according to claim 1, It is characterized in that In step (4), after the reaction is completed, the temperature is lowered, an extractant is added for extraction, the extract is cooled and crystallized, and the compound D is obtained by filtration. The extractant is selected from petroleum ether, hexane, heptane, octane, benzene or toluene.

7. The method for preparing the cationic liposome SM-102 and Lipid5 according to claim 1, It is characterized in that In step (5), the organic solvent C is selected from acetonitrile, methanol, ethanol, propanol or isopropanol; the catalyst D is selected from anhydrous potassium carbonate, anhydrous sodium carbonate, anhydrous potassium bicarbonate or anhydrous sodium bicarbonate, and the mass ratio of catalyst D to compound D is 10-60:

100.

8. The method for preparing the cationic liposome SM-102 and Lipid5 according to claim 1, It is characterized in that In step (6), the organic acid is selected from tartaric acid, fumaric acid, maleic acid, citric acid, oxalic acid, succinic acid or benzoic acid, and the molar ratio of the crude compound E to the organic acid is 1:1-2; the recrystallization solvent is selected from petroleum ether, hexane, heptane, octane, benzene or toluene; and the base B is aqueous ammonia.

9. The method for preparing the cationic liposome SM-102 and Lipid5 according to claim 1, It is characterized in that The organic acid is fumaric acid.

10. The method for preparing the cationic liposome SM-102 and Lipid5 according to claim 1, It is characterized in that The method comprises: (1) 8-bromooctanoic acid and methanol are subjected to esterification reaction under the action of concentrated sulfuric acid at a reaction temperature of 20-70° C. After the reaction is completed, sodium carbonate is added to adjust the reaction to alkalinity, the reaction is filtered, and the methanol is recovered to obtain 8-bromooctanoic acid methyl ester. The mass ratio of methanol to 8-bromooctanoic acid is 1-10:1, and the amount of concentrated sulfuric acid used is 0.1-5% of the mass of 8-bromooctanoic acid; (2) in n-heptane, 8-bromooctanoic acid methyl ester and 9-heptadecanol are subjected to ester exchange reaction under the action of propylene oxide, the reaction temperature is 80-90° C., after the reaction is completed, the n-heptane is recovered to obtain 8-bromooctanoic acid-9-heptadecanol ester, the molar ratio of 8-bromooctanoic acid methyl ester to 9-heptadecanol is 1:1.05-2, and the amount of propylene oxide used is 0.1-3% of the mass of 8-bromooctanoic acid methyl ester; (3) Compound A and Compound B react under the action of potassium hydrogen sulfate at a reaction temperature of 60-100° C. and a reaction pressure of 10-20 mmHg. After the reaction is completed, the compound C is obtained by filtration. The molar ratio of compound A to compound B is 1:1.05-2, and the amount of potassium hydrogen sulfate used is 0.1-10% of the mass of compound A; (4) reacting compound C with ethanolamine in ethanol at a reaction temperature of 20-50° C., cooling after the reaction is completed, extracting with n-heptane, crystallizing the extract at -10-5° C., filtering to obtain compound D, wherein the molar ratio of compound C to ethanolamine is 1:5-15; (5) In acetonitrile, compound D and 8-bromooctanoic acid-9-heptadecanol ester are subjected to an amination reaction under the action of anhydrous potassium carbonate and under nitrogen protection, the reaction temperature is 60-85° C. After the reaction is completed, the mixture is filtered, rinsed with n-hexane or n-heptane, fumaric acid is added to the filtrate, the temperature is reduced for crystallization, filtered, the solid is recrystallized from n-hexane or n-heptane, ammonia water is added to adjust the pH value to alkaline, anhydrous sodium sulfate is added to dry until the solution is clear, filtered, and n-hexane or n-heptane is recovered to obtain compound E, wherein the molar ratio of compound D to 8-bromooctanoic acid-9-heptadecanol ester is 1:1.05-2.5, the mass ratio of anhydrous potassium carbonate to compound D is 10-60:100, and the molar ratio of crude compound E to fumaric acid is 1:1.05-2.

Citation Information

Patent Citations

  • Compounds and compositions for intracellular delivery of therapeutic agents

    WO2017049245A2

  • Lipid nanoparticle formulations

    WO2018081480A1

  • Ionizable amine lipids

    CN113039174A

  • Long-chain alkyl ester amine compound or fluorine-containing long-chain alkyl ester amine compound and kilogram-level preparation method thereof

    CN113387825A

  • mRNA combination therapy for the treatment of cancer

    US20180369374A1